View abstract

Cet abstract a été assigné à session BIO: Belgian Immuno Ophthalmology Club
TitreFRO: Development of a next-generation sequencing platform for retinal dystrophies, with LCA and RP as proof of concept.
ButLeber Congenital Amaurosis (LCA) is a rare congenital retinal dystrophy associated with 16 genes. Recent breakthroughs in LCA gene therapy offer the first prospect of treating inherited blindness, which requires an unequivocal and early molecular diagnosis. While present genetic tests do not address this due to a tremendous genetic heterogeneity, massively parallel sequencing (MPS) strategies might bring a solution. Here, we developed a comprehensive molecular test for LCA based on targeted MPS of all exons of 16 known LCA genes.
MéthodesWe designed a unique and flexible workflow for targeted resequencing of all 236 exons from 16 LCA genes based on qPCR amplicon ligation, shearing and parallel sequencing of multiple patients on a single lane of a short read sequencer. Twenty-two pre-screened LCA patients were included, five of which with known molecular cause.
RésultatsValidation of 107 variations was performed as proof of concept. In addition, the causal genetic defect and a single heterozygous mutation were identified in 3 and 5 out of 17 patients without previously identified mutations, respectively.
ConclusionWe propose a novel targeted MPS-based approach that is suitable for accurate, fast and cost-effective early molecular testing in LCA, and easily applicable in other genetic disorders.
Auteur 1
NomCOPPIETERS
InitialesF
InstitutCenter for Medical Genetics Ghent, Ghent University
VilleGhent
top ^